

# INDEX

Contents .....	I-VI
List of Tables .....	VII-XIV
List of Figures .....	XV-XIX
List of Abbreviations .....	XX-XXI
<b>Chapter 1. Introduction.....</b>	<b>1-11</b>
1.1 Oral drug delivery.....	1
1.2 Multiple Unit Particulate System (MUPS).....	1
1.3 Chronic Disorders.....	3
1.3.1 Drawbacks encountered in chronic therapy.....	3
1.3.2 Cardio vascular disorders.....	4
1.3.3 Diabetes .....	5
1.4 Problems associated with Metoprolol succinate and Metformin hydrochloride.....	6
1.4.1 Dosing frequency/ Plasma drug levels.....	6
1.4.2 Life cycle management.....	6
1.5 Quality by design (QbD).....	8
1.6 Objective .....	8
1.7 Hypothesis.....	9
1.8 Plan of work.....	9
<b>Chapter 2. Literature Review.....</b>	<b>12-58</b>
2.1 Multiparticulate drug delivery systems (MDDS).....	12
2.1.1 Salient aspects of pellets.....	12
2.1.2 Fluidized bed (air suspension) systems.....	20
2.1.3 Parameters affecting fluidized bed coating.....	22
2.2 Dysphagia.....	24
2.2.1 Statistics for Dysphagia.....	26
2.3 Product life cycle.....	27
2.4 Life Cycle Management.....	28
2.4.1 History of LCM.....	29
2.4.2 LCM –importance to pharmaceutical industry.....	29
2.4.3 Example of LCM in pharmaceutical industry.....	30

2.5	Quality by Design (QbD).....	36
2.6	Design of Experiments.....	38
2.7	Drug Profiles.....	40
2.7.1	Metoprolol Succinate.....	40
2.7.2	Metformin Hydrochloride.....	46
2.8	Excipients Profile.....	52
2.9	Conclusion.....	52
<b>Chapter 3. Analytical Techniques.....</b>		<b>59-93</b>
3.1	Introduction.....	59
3.2	Materials, Instruments and Reagents.....	59
3.2.1	Materials.....	59
3.2.2	Instruments and softwares.....	60
3.2.3	Reagents / solutions.....	60
3.3	Methods.....	61
3.3.1	Estimation of MS by UV Spectrophotometric methods.....	61
3.3.2	Validation of UV Spectrophotometric methods.....	62
3.3.3	Estimation of MS in plasma by HPLC method.....	64
3.3.4	Validation of HPLC Method.....	65
3.3.5	Estimation of MH by UV Spectrophotometric methods.....	65
3.3.6	Validation of UV Spectrophotometric methods.....	66
3.3.7	Estimation of MH in plasma by HPLC method.....	66
3.3.8	Validation of HPLC Method.....	67
3.4	Results & Discussion.....	67
3.4.1	Estimation of MS by UV Spectrophotometry.....	67
3.4.2	Validation of UV Spectrophotometric Methods.....	68
3.4.3	Estimation of MS in plasma by HPLC Method.....	75
3.4.4	Validation of HPLC Method.....	76
3.4.5	Estimation of MH by UV Spectrophotometry.....	79
3.4.6	Validation of UV Spectrophotometric Methods.....	81
3.4.7	Estimation of MH in plasma by HPLC Method.....	88
3.4.8	Validation of HPLC Method.....	88
3.5	Conclusions.....	91

## **Chapter 4. Formulation Development (MUPS) - Part A: Experimental.....94-137**

4.1	Materials and Equipments.....	94
4.1.1	Materials.....	94
4.1.2	Equipments.....	94
4.2	Preformulation.....	95
4.2.1	Authentication of drugs.....	95
4.2.2	Drug-Excipients Compatibility Study.....	95
4.3	Formulation Development.....	96
4.3.1	Quality Target Product Profile (QTPP).....	97
4.3.2	Initial Risk assessment by Failure Mode and Effects Analysis (FMEA).....	98
4.3.3	Selection of core material.....	99
4.3.4	Selection of load.....	100
4.3.5	Drug loading.....	100
4.3.6	Controlled release (CR) coating.....	108
4.3.7	Selection of core pellet size.....	111
4.3.8	Selection of core pellet quantity per unit.....	114
4.3.9	Selection of controlled release (CR) polymer.....	115
4.3.10	Reservoir Vs Matrix technique.....	117
4.3.11	Optimization of drug + CR polymer coating solution solid content.....	122
4.3.12	Extent of CR coating and drug: polymer ratio in matrix system.....	123
4.3.13	Curing time.....	124
4.3.14	Design of Experiment.....	125
4.3.15	Risk mitigation and control strategy.....	126
4.3.16	Eudragit® E coating.....	127

## **Chapter 4. Formulation Development (MUPS)-Part B: Results & Discussion138-208**

4.4	Preformulation.....	138
4.4.1	Authentication of drugs: Metoprolol Succinate (MS) and Metformin HCl (MH) .....	138
4.4.2	Drug-Excipients Compatibility Study.....	142
4.5	Formulation Development.....	148
4.5.1	Quality Target Product Profile (QTPP).....	148
4.5.2	Failure Mode and Effects Analysis (FMEA).....	148

4.5.3	Selection of core material .....	149
4.5.4	Selection of load.....	150
4.5.5	Drug Loading.....	151
4.5.6	Controlled release coating .....	157
4.5.7	Selection of core pellet size.....	159
4.5.8	Selection of core pellet quantity per unit.....	162
4.5.9	Selection of controlled release (CR) polymer.....	165
4.5.10	Reservoir Vs Matrix techniques.....	168
4.5.11	Optimization for solid content of coating solution in matrix system.....	173
4.5.12	Extent of CR coating and drug: polymer ratio in matrix system.....	174
4.5.13	Curing time.....	178
4.5.14	Design of Experiment.....	181
4.5.15	Risk mitigation and control strategy.....	192
4.5.16	Eudragit® E coating.....	193

**Chapter 5. Formulation Development – Part A: CRPFR.....209-224**

5.1	Materials and Equipments.....	209
5.1.1	Materials.....	209
5.1.2	Equipments.....	209
5.2	Formulation of Controlled Release Powder for Reconstitution.....	209
5.2.1	Selection of suspending agent.....	210
5.2.2	Selection of alkalizer.....	212
5.2.3	Selection of flavor and color.....	214
5.2.4	Drug leaching study.....	214
5.2.5	Minimization of drug leaching.....	214
5.2.6	Flow characterization of CRPFR.....	216
5.2.7	Evaluation of reconstituted suspension .....	216
5.2.8	Packaging and stability study.....	217
5.3	Results and discussion for MS and MH Controlled Release Powder for Reconstitution.....	218
5.3.1	Selection of suspending agent.....	218
5.3.2	Selection of alkalizer.....	218
5.3.3	Drug leaching study.....	219

5.3.4	Minimization of drug leaching study.....	219
5.3.5	Flow characterization of PFR.....	220
5.3.6	Evaluation of final reconstituted suspension.....	220
5.3.7	Packaging and stability study.....	221
<b>Chapter 5. Formulation Development – Part B: CRODT.....</b>		<b>225-248</b>
5.4	Materials and Equipments.....	225
5.4.1	Materials.....	225
5.4.2	Equipments.....	225
5.5	Controlled Release Orally Disintegrating Tablet (CRODT).....	226
5.5.1	Fabrication of CRODT.....	226
5.5.2	Selection of superdisintegrants.....	227
5.5.3	Selection of diluents.....	229
5.5.4	Optimization of super disintegrant level.....	230
5.5.5	Optimization of cushioning agent to prevent rupture of MS and MH pellets.....	232
5.5.6	Packaging and stability study.....	233
5.6	Results and discussion for MS and MH Controlled Release Orally Disintegrating Tablet.....	234
5.6.1	Selection of superdisintegrants.....	234
5.6.2	Selection of diluents.....	235
5.6.3	Optimization of super disintegrant level to achieve fast disintegration....	236
5.6.4	Optimization of cushioning agent and prevention of rupture of pellets...	239
5.6.5	Characterization of blend.....	244
5.6.6	Packaging and stability study.....	245
<b>Chapter 6. <i>In Vivo</i> Studies.....</b>		<b>249-256</b>
6.1	Introduction.....	249
6.2	Methods.....	249
6.2.1	Protocol approval.....	249
6.2.2	Animals.....	249
6.2.3	Pharmacokinetic study of MS formulations.....	249
6.2.4	Pharmacokinetic study of MH formulations.....	250
6.3	Results & Discussion.....	251

6.3.1	Pharmacokinetic study of MS formulations.....	251
6.3.2	Pharmacokinetic study of MH formulations.....	253
6.4	Conclusion.....	255
<b>Chapter 7. Summary and conclusions.....</b>		<b>257-268</b>
7.1	Aim.....	258
7.2	Preformulation.....	258
7.3	Analytical Method Development.....	258
7.3.1	UV spectrophotometric methods.....	258
7.3.2	HPLC methods.....	259
7.4	Formulation Development of MS and MH-MUPS.....	259
7.4.1	Eudragit® E coated MUPS.....	261
7.5	Formulation Development of CRPFR- MS and MH.....	263
7.6	Formulation Development of CRODT- MS and MH.....	264
7.7	Pharmacokinetic Studies .....	265
7.7.1	Metoprolol Succinate.....	266
7.7.2	Metformin Hydrochloride.....	266
7.8	Conclusions.....	267
7.9	Future perspective of present study.....	268
<b>Appendix I.....</b>		<b>I-XIX</b>
<b>Appendix II.....</b>		<b>XX-XXI</b>